Mapping the neuroanatomy of ABHD16A-ABHD12 & lysophosphatidylserines provides new insights into the pathophysiology of the human neurological disorder PHARC.

@article{Singh2020MappingTN,
  title={Mapping the neuroanatomy of ABHD16A-ABHD12 \& lysophosphatidylserines provides new insights into the pathophysiology of the human neurological disorder PHARC.},
  author={Shubham Singh and Alaumy Joshi and Siddhesh S. Kamat},
  journal={Biochemistry},
  year={2020}
}
Lysophosphatidylserine (lyso-PS), a lysophospholipid derived from phosphatidylserine (PS), has emerged as a potent signaling lipid in mammalian physiology. In vivo, the metabolic serine hydrolases ABHD16A and ABHD12 are major lipases that biosynthesize and degrade lyso-PS respectively. Of biomedical relevance, deleterious mutations to ABHD12 causes accumulation of lyso-PS in the brain, and this deregulated lyso-PS metabolism leads to the human genetic neurological disorder PHARC (polyneuropathy… 
Discovery and Optimization of Selective and in Vivo Active Inhibitors of the Lysophosphatidylserine Lipase α/β-Hydrolase Domain-Containing 12 (ABHD12).
TLDR
The in vitro and in vivo properties of DO264 designate this compound as a suitable chemical probe for studying the biological functions of ABHD12-(lyso)-PS/PI pathways.
Current Knowledge on the Biology of Lysophosphatidylserine as an Emerging Bioactive Lipid
TLDR
Modulation of LysoPS signaling appears to be a promising method for providing therapies for the treatment of immune diseases.
The Lysophosphatidylserines—An Emerging Class of Signalling Lysophospholipids
TLDR
Studies that led to the discovery of lyso-PS as a potent signalling biomolecule are summarized and the structure, its detection in biological systems, and the biodistribution of this lysophospholipid in various mammalian systems are discussed.
Increase in Cellular Lysophosphatidylserine Content Exacerbates Inflammatory Responses in LPS-Activated Microglia.
TLDR
The results suggest that increase in cellular LysoPS levels can exacerbate microglial inflammatory responses and treatment to prevent the increase in Cellular Lyso PS in microglia may have therapeutic potential for PHARC.
Emerging Role of Phospholipids and Lysophospholipids for Improving Brain Docosahexaenoic Acid as Potential Preventive and Therapeutic Strategies for Neurological Diseases
TLDR
The aim of this review was to develop a complete understanding of previous and current approaches and suggest future approaches to target the brain with DHA in different lipids’ forms for potential prevention and treatment of neurodegenerative diseases.
α/β-Hydrolase Domain (ABHD) Inhibitors as New Potential Therapeutic Options against Lipid-Related Diseases
TLDR
This Perspective summarizes the research progress in the development of ABHD inhibitors and modulators: design strategies, structure-activity relationships, action mechanisms, and biological studies of the main ABHD ligands will be highlighted.
Functional annotation of ABHD14B, an orphan serine hydrolase enzyme.
TLDR
Annotation of ABHD14B as a lysine deacetylase (KDAC) is annotated, showing this enzyme's ability in transferring an acetyl group from a post-translationally acetylated-lysine to coenzyme A (CoA), to yield acetyl-CoA, while re-generating the free amine of proteinLysine residues.
Pathogenic Variants in ABHD16A Cause a Novel Psychomotor Developmental Disorder With Spastic Paraplegia
TLDR
A loss of function in ABHD16A encodes the main brain phosphatidylserine hydrolase is implicated in the pathogenesis of a novel form of complex hereditary spastic paraplegia.
...
...

References

SHOWING 1-10 OF 52 REFERENCES
Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay
TLDR
A small-molecule inhibitor of ABHD16A that depletes lyso-PSs from cells, including lymphoblasts derived from subjects with PHARC, and these enzymes are designated as potential targets for treating neuroimmunological disorders.
ABHD12 and LPCAT3 Interplay Regulates a Lyso-phosphatidylserine-C20:4 Phosphatidylserine Lipid Network Implicated in Neurological Disease.
TLDR
It is shown that genetic deletion of the lysophospholipid acyltransferase LPCAT3 blocks accumulation of brain C20:4 PS in mice lacking ABHD12 and concurrently produces hyper-increases in the level of lyso-PS in these animals.
Selective blockade of the lyso-PS lipase ABHD12 stimulates immune responses in vivo
TLDR
A selective and in vivo–active inhibitor of ABHD12 termed DO264 is developed and it is shown that this compound elevates lyso-PS in mouse brain and primary human macrophages and point to a key role for this enzyme in regulating immunostimulatory lipid pathways in vivo.
ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC
TLDR
Untargeted metabolomics combined with a genetic mouse model is used to determine that the poorly characterized serine hydrolase α/β-hydrolase domain-containing (ABHD)12, mutations in which cause the human neurodegenerative disorder PHARC, is a principal LPS lipase in the mammalian brain.
Biochemical characterization of the PHARC-associated serine hydrolase ABHD12 reveals its preference for very-long-chain lipids
TLDR
The facile synthesis of mono-1-(fatty)acyl-glycerol lipids of varying chain lengths and unsaturation is reported and this lipid substrate library is used to biochemically characterize recombinant mammalian ABHD12.
Discovery and Optimization of Selective and in Vivo Active Inhibitors of the Lysophosphatidylserine Lipase α/β-Hydrolase Domain-Containing 12 (ABHD12).
TLDR
The in vitro and in vivo properties of DO264 designate this compound as a suitable chemical probe for studying the biological functions of ABHD12-(lyso)-PS/PI pathways.
Blockade of the Lysophosphatidylserine Lipase ABHD12 Potentiates Ferroptosis in Cancer Cells.
TLDR
screened a panel of inhibitors of serine hydrolases for potentiation of ferroptosis in HT1080 fibrosarcoma cells and found that DO264, a selective inhibitor of the lyso- and ox-phosphatidylserine (PS) lipase ABHD12, enhances ferroPTotic death caused by RSL3, an inhibitors of the lipid peroxidase GPX4.
Lysophosphatidylserine stimulates chemotactic migration of colorectal cancer cells through GPR34 and PI3K/Akt pathway.
TLDR
The involved receptor and pathways in the migratory ability in response to lysoPS was demonstrated, which opens premises for targeting as a new strategy for prevention and treatment of colorectal cancer.
...
...